We are live on ! Find out more
WST icon

West Pharmaceutical

222 hedge funds and large institutions have $2.74B invested in West Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 98 increasing their positions, 75 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more call options, than puts

Call options by funds: $346K | Put options by funds: $257K

31% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 75

1.76% more ownership

Funds ownership: 90.2%91.96% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

2% less capital invested

Capital invested by funds: $2.81B → $2.74B (-$65.6M)

2% less funds holding

Funds holding: 226222 (-4)

17% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 24

Holders
222
Holders Change
-4
Holders Change %
-1.77%
% of All Funds
6.38%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
20
Increased
98
Reduced
75
Closed
24
Calls
$346K
Puts
$257K
Net Calls
+$89K
Net Calls Change
-$70K
Name Holding Trade Value Shares
Change
Change in
Stake
SM
26
Stratton Management
Pennsylvania
$29.6M +$2.91M +67,900 +11%
Schroder Investment Management Group
27
Schroder Investment Management Group
United Kingdom
$28.4M +$14.9M +348,000 +107%
Ameriprise
28
Ameriprise
Minnesota
$28.3M +$1.1M +25,790 +4%
ICM
29
IronBridge Capital Management
Illinois
$28.1M -$5.37M -125,405 -16%
KCM
30
Kennedy Capital Management
Missouri
$25.5M -$1.34M -31,275 -5%
EAM
31
Eagle Asset Management
Florida
$23M +$3.94M +92,062 +20%
O
32
OppenheimerFunds
New York
$22.4M +$1.15M +26,770 +5%
ACM
33
Atlanta Capital Management
Georgia
$22.2M +$2.55M +59,473 +13%
Lord, Abbett & Co
34
Lord, Abbett & Co
New Jersey
$19.1M -$3.36M -78,400 -15%
EVM
35
Eaton Vance Management
Massachusetts
$18.9M +$17.6M +411,687 +1,096%
Principal Financial Group
36
Principal Financial Group
Iowa
$18.8M -$138K -3,228 -0.7%
SAM
37
Silvercrest Asset Management
New York
$17.3M -$11.9M -278,184 -40%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$16.8M -$1.97M -45,967 -10%
Prudential Financial
39
Prudential Financial
New Jersey
$16.7M -$130K -3,034 -0.8%
CRCP
40
Copper Rock Capital Partners
Massachusetts
$15.7M -$8.17M -190,694 -34%
TCIM
41
TIAA CREF Investment Management
New York
$14.9M +$166K +3,868 +1%
Deutsche Bank
42
Deutsche Bank
Germany
$10.4M +$939K +21,928 +10%
Morgan Stanley
43
Morgan Stanley
New York
$10.4M +$1.89M +44,128 +22%
MAA
44
Managed Account Advisors
New Jersey
$10.3M +$278K +6,495 +3%
RCM
45
Rutabaga Capital Management
Massachusetts
$10M +$306K +7,135 +3%
Charles Schwab
46
Charles Schwab
California
$9.96M -$1.05M -24,540 -9%
BIM
47
BlackRock Investment Management
Delaware
$9.78M +$81.5K +1,902 +0.8%
NFA
48
Nationwide Fund Advisors
Ohio
$9.52M +$516K +12,054 +6%
Invesco
49
Invesco
Georgia
$8.47M -$35M -818,408 -80%
TLCM
50
Tiger Legatus Capital Management
New York
$7.59M +$1.71M +40,000 +29%

WST Hedge Fund Activity: Q2 2014 in Review

222 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2014, worth a combined $2.74B — down 2.3% from $2.81B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of WST and 20 opened new positions — a net loss of 4 holders — while 75 trimmed existing stakes and 98 added.

The largest buyer was RS Investment Management, adding an estimated $21.9M. The largest seller was Invesco, cutting an estimated $35M.

  • 222 institutional investors held West Pharmaceutical (WST) as of Q2 2014, down from 226 in Q1 2014.
  • Funds reported $2.74B of West Pharmaceutical stock for Q2 2014, down 2.3% quarter-over-quarter.
  • 20 funds opened new West Pharmaceutical positions in Q2 2014 and 24 closed out, a net change of -4 holders.
  • The largest West Pharmaceutical buyer in Q2 2014 was RS Investment Management, an estimated $21.9M added.
  • The largest West Pharmaceutical seller in Q2 2014 was Invesco, an estimated $35M sold.

Based on aggregated 13F filings for Q2 2014.